Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

P4-07-13: Prognostic Impact of Circulating Tumor Cells Assessed with the Cell Search Assay and Adna Test Breast in Metastatic Breast Cancer Patients – The DETECT Study.

View through CrossRef
Abstract Background Over the last decade circulating tumor cells (CTC) were established as a prognostic factor in breast cancer patients. However, there are very limited studies comparing different test methods, although several are available.The DETECT trial for metastatic breast cancer patients was designed to investiate the prognostic impact of CTC. Here, we report on the prognostic relevance of CTC testing with different detection methods. Material and Methods: Patients with primary metastatic breast cancer or metastatic recurrence were prospectively enrolled in this multicenter trial. CTC were detected using the FDA-approved Cell Search® assay applying immunocytochemistry and the RNA-based Adna Test Breast Cancer™. After a median follow-up of 11 months the first survival data are now presented. Results: Both methods could be performed in 221 patients. Using the CellSearch™ assay 116 of 221 patients were CTC-positive based on the cut-off level of 5 cells. Presence of CTC was associated with the site of metastatic disease. The OS was 15.4 months in CTC positive pts. (95%-CI: 13.5−17.1 mths) compared to 20.4 mths. in CTC negative pts. (19.1−21.9 mths.; p<0.001). In the multivariate analysis presence of CTC was the only independent predictor for overall survival (HR: 3.4, 95%-CI: 1.7−6.3) including tumorbiological factors, menopausal status, number and sites of metastatic disease. The progression-free survival was not correlated with CTC status in our cohort receiving different types of systemic treatment (p=0.197). When the AdnaTest Breast was performed, 88 of 221 (40%) patients were CTC positive. Except for HER2 status, no correlation could be observed between CTC positivity and any of the clinicopathological factors. CTC positivity assessed by the AdnaTest Breast has no impact on PFS and OS. A multivariate analysis was therefore not performed. Conclusions: Currently, several different tests are available for CTC detection. Only a few tests have been approved by the FDA and been validated in large clinical trials. Therfore, it will be important to compare new techniques with the Cell Search assay. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-07-13.
Title: P4-07-13: Prognostic Impact of Circulating Tumor Cells Assessed with the Cell Search Assay and Adna Test Breast in Metastatic Breast Cancer Patients – The DETECT Study.
Description:
Abstract Background Over the last decade circulating tumor cells (CTC) were established as a prognostic factor in breast cancer patients.
However, there are very limited studies comparing different test methods, although several are available.
The DETECT trial for metastatic breast cancer patients was designed to investiate the prognostic impact of CTC.
Here, we report on the prognostic relevance of CTC testing with different detection methods.
Material and Methods: Patients with primary metastatic breast cancer or metastatic recurrence were prospectively enrolled in this multicenter trial.
CTC were detected using the FDA-approved Cell Search® assay applying immunocytochemistry and the RNA-based Adna Test Breast Cancer™.
After a median follow-up of 11 months the first survival data are now presented.
Results: Both methods could be performed in 221 patients.
Using the CellSearch™ assay 116 of 221 patients were CTC-positive based on the cut-off level of 5 cells.
Presence of CTC was associated with the site of metastatic disease.
The OS was 15.
4 months in CTC positive pts.
(95%-CI: 13.
5−17.
1 mths) compared to 20.
4 mths.
in CTC negative pts.
(19.
1−21.
9 mths.
; p<0.
001).
In the multivariate analysis presence of CTC was the only independent predictor for overall survival (HR: 3.
4, 95%-CI: 1.
7−6.
3) including tumorbiological factors, menopausal status, number and sites of metastatic disease.
The progression-free survival was not correlated with CTC status in our cohort receiving different types of systemic treatment (p=0.
197).
When the AdnaTest Breast was performed, 88 of 221 (40%) patients were CTC positive.
Except for HER2 status, no correlation could be observed between CTC positivity and any of the clinicopathological factors.
CTC positivity assessed by the AdnaTest Breast has no impact on PFS and OS.
A multivariate analysis was therefore not performed.
Conclusions: Currently, several different tests are available for CTC detection.
Only a few tests have been approved by the FDA and been validated in large clinical trials.
Therfore, it will be important to compare new techniques with the Cell Search assay.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-07-13.

Related Results

Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract Introduction Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Coexisting Granulomatous Mastitis and Breast Cancer: A Systematic Review
Coexisting Granulomatous Mastitis and Breast Cancer: A Systematic Review
Abstract Introduction: Granulomatous mastitis (GM) is a rare inflammatory breast disease that mimics carcinoma. GM can coexist with breast cancer (BC), though the relationship rema...
Desmoid-Type Fibromatosis of The Breast: A Case Series
Desmoid-Type Fibromatosis of The Breast: A Case Series
Abstract IntroductionDesmoid-type fibromatosis (DTF), also called aggressive fibromatosis, is a rare, benign, locally aggressive condition. Mammary DTF originates from fibroblasts ...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Spanish Breast Cancer Research Group (GEICAM)
Spanish Breast Cancer Research Group (GEICAM)
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Spanish Breast Cancer Research Group (GEICAM). Clinical trials...
YAP1 and downstream gene alterations in metastatic breast cancer.
YAP1 and downstream gene alterations in metastatic breast cancer.
e13121 Background: Metastatic breast cancer remains a major clinical challenge, characterized by poor prognosis and limited therapeuti...

Back to Top